Kidney Transplant Rejection
95
13
23
25
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.6%
11 terminated out of 95 trials
69.4%
-17.1% vs benchmark
11%
10 trials in Phase 3/4
28%
7 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 25 completed trials
Clinical Trials (95)
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
Microbiome and Immunosuppression: The Mission Study
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Trifecta-Kidney cfDNA-MMDx Study
Observational Cohort Study Renal Transplantation University Hospitals Leuven
Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Using MSCs for Chronic Active Antibody Mediated Rejection
AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection